Crohn’s Disease

August 17, 2015August 17, 2015

RedHill Biopharma Presents Crohn’s Disease Therapeutics Program at International Research Symposium

Crohn's Disease, News

Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently presented its RHB-104 Phase III Crohn’s disease program at the International Research Symposium for Game Changing Concepts in Crohn’s Medicine on Sunday, August 16, 2015 ... Read more

August 10, 2015August 10, 2015

Bioelectronic Low-Level Electric Pulse Reduces Systemic Inflammation in Diseases Such as Crohn’s Disease

Crohn's Disease, News

In a new study entitled “Single-pulse and unidirectional electrical activation of the cervical vagus nerve reduces tumor necrosis factor in endotoxemia,” scientists discovered that a low-level electrical stimulation of body’s ... Read more

August 7, 2015August 7, 2015

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Crohn's Disease, News

Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase ... Read more

July 31, 2015July 31, 2015

Differences in Cell-Signaling Protein Production Levels Do Not Affect Disease Type in Quiescent Crohn’s Disease

Crohn's Disease, News

A new study on Crohn’s Disease revealed that individual differences in innate cytokine production are not important in the development of Quiescent Crohn’s Disease. The study entitled “LPS-Stimulated Whole Blood Cytokine Production ... Read more

July 9, 2015September 28, 2016

Tillotts Pharma AG To Acquire Global Rights for Entocort (budesonide) Outside The U.S. Under Agreement With AstraZeneca

Crohn's Disease, News

Rheinfelden, Switzerland based Tillotts Pharma AG (“Tillotts”), part of Japan’s Zeria Group, has announced its entry into an agreement in which it will acquire global rights from London based AstraZeneca ... Read more

July 8, 2015September 28, 2016

New Device to Transform Lives of Bowel Disease Patients Launched

Crohn's Disease, News, Ulcerative colitis

British medical technology firm 11health has announced UK availability of what it claims is the first ever patient-developed medical technology device. The Ostom-i Alert is projected to help the roughly ... Read more

July 7, 2015July 7, 2015

RedHill Biopharma Authorized to Test RHB-104 for Crohn’s Disease in Australia and New Zealand

Crohn's Disease, News

Israel-based RedHill Biopharma Ltd. recently disclosed it has been granted authorization to begin enrolling patients in Australia and New Zealand for a Phase III clinical trial designed to test RHB-104 as a ... Read more

July 2, 2015July 2, 2015

RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate

Crohn's Disease, News

Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently announced its acquisition of two notices of allowance from the United States Patent and Trademark Office (USPTO) covering patient application numbers 13/722,395 and 14/271,758 for RHB-104, ... Read more

June 25, 2015June 25, 2015

Vitamin D Protects Against Inflammation in Crohn’s Disease, Helps Maintain Intestinal Permeability

Crohn's Disease, News

In a new study entitled “Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomized double-blind placebo-controlled study,” researchers revealed how Vitamin D ... Read more

June 17, 2015September 28, 2016

RedHill Announces MHRA Acceptance of Clinical Trial Application for Phase III clinical trial of RHB-104 in Crohn’s Disease

Crohn's Disease, News

RedHill Biopharma Ltd., an emerging biopharmaceutical company based in Israel focused on the development of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, recently announced that the UK ... Read more